Log in
Enquire now
VarmX

VarmX

VarmX is a Netherlands-based biotechnology company manufacturing therapeutic proteins to restore blood clotting in bleeding patients.

OverviewStructured DataIssuesContributors

Contents

varmx.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Biology
Biology
Therapeutics
Therapeutics
‌
Pharmaceuticals
Engineering
Engineering
Biomedical engineering
Biomedical engineering
Technology
Technology
Biotechnology
Biotechnology
Location
Leiden
Leiden
0
B2X
B2B
B2B
0
CEO
‌
Jan Öhrström
0
Founder
‌
Paul Bilars
‌
Pieter Reitsma
0
Number of Employees (Ranges)
1 – 10
Email Address
info@varmx.com0
p.bilars@varmx.com
Full Address
Middelweg 38 B 2312 KJ Leiden The Netherlands0
Investors
InnovationQuarter
InnovationQuarter
Sound Bioventures
Sound Bioventures
EIC Accelerator
EIC Accelerator
Inkef Capital
Inkef Capital
Ysios Capital
Ysios Capital
BioGeneration Ventures
BioGeneration Ventures
UNIQ (company)
UNIQ (company)
Lundbeckfonden Ventures
Lundbeckfonden Ventures
Founded Date
2016
Total Funding Amount (USD)
93,773,000
Latest Funding Round Date
May 25, 2023
Former CEO
‌
Paul Bilars
Latest Funding Type
Series B
Series B
Country
Netherlands
Netherlands
0
Headquarters
The Hague
The Hague

Other attributes

Company Operating Status
Active
Latest Funding Round Amount (USD)
37,000,000

VarmX is a spin-off of the Leiden University Medical Center. VarmX is a company that has the mission to develop and manufacture therapeutic proteins in order to restore hemostasis. VarmX focuses on the development of therapies in the areas of hemostasis and thrombosis. The company develops therapeutic drugs that have been designed to restore blood clotting in bleeding patients.

The company's drugs are modified recombinant human coagulation factor which are capable of restoring blood clotting in the presence of direct factor anticoagulants such as rivaroxaban, apixaban and edoxaban, enabling physicians to safely and effectively restore hemostasis in case of bleeding.

VarmX’s lead compound, VMX-COO1, is developed to safely and effectively restore hemostasis in case of bleeding or emergency surgery in patients taking so-called oral factor Xa inhibitors. The drug contains modified natural coagulation factor that can instantly and efficiently restore blood clotting in patients taking anticoagulants.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like VarmX

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.